Amedeo Smart

Free Medical Literature Service

 

Amedeo

Depression
  Free Subscription

Articles published in
BMJ
    October 2025
  1. DOSHI P
    Notorious GSK paroxetine adolescent depression trial is slapped with expression of concern amid legal action.
    BMJ. 2025;391:r2279.
    >> Share

  2. MAHASE E
    Sertraline study shows mixed effect on depression symptoms.
    BMJ. 2025;391:r2294.
    >> Share

  3. TAYLOR L
    WHO: Third of European doctors and nurses have depression or anxiety.
    BMJ. 2025;391:r2156.
    >> Share

    September 2025

  4. Medical news in brief: Surgeon is jailed for amputation fraud, first pill for postnatal depression, Ebola in DRC, and other stories.
    BMJ. 2025;390:r1892.
    >> Share

    August 2025
  5. BOWIE K
    Postnatal depression: First pill treatment is approved in UK.
    BMJ. 2025;390:r1826.
    >> Share

  6. DEAN E
    "I was suicidal"-the consultant psychiatrist opening up the conversation on postnatal depression.
    BMJ. 2025;390:r1449.
    >> Share

    July 2025
  7. ARETOULI E, Malik M, Widmann C, Parker AM, et al
    Cognitive and mental health outcomes in long covid.
    BMJ. 2025;390:e081349.
    >> Share

    April 2025
  8. FRAIS T
    Finding the right treatment for severe depression.
    BMJ. 2025;389:r478.
    >> Share

    February 2025

  9. CORRECTION: Efficacy of psilocybin for treating symptoms of depression: systematic review and meta-analysis.
    BMJ. 2025;388:r111.
    >> Share

    October 2024
  10. NOLAN T
    CBT for postnatal depression ... and other research.
    BMJ. 2024;387:q2308.
    >> Share

    September 2024
  11. HAUN MW, Tonnies J, Hartmann M, Wildenauer A, et al
    Model of integrated mental health video consultations for people with depression or anxiety in primary care (PROVIDE-C): assessor masked, multicentre, randomised controlled trial.
    BMJ. 2024;386:e079921.
    >> Share

    August 2024
  12. ZHANG Y, Wang H, Wu S, Xiao Y, et al
    Empowering new mothers in China: role of paediatric care in screening and management of postpartum depression.
    BMJ. 2024;386:e078636.
    >> Share

  13. HSU TW, Tsai CK, Kao YC, Thompson T, et al
    Comparative oral monotherapy of psilocybin, lysergic acid diethylamide, 3,4-methylenedioxymethamphetamine, ayahuasca, and escitalopram for depressive symptoms: systematic review and Bayesian network meta-analysis.
    BMJ. 2024;386:e078607.
    >> Share

  14. WISE J
    Sixty seconds on . . . antidepression headsets.
    BMJ. 2024;386:q1784.
    >> Share

    July 2024
  15. NJENGA C, Ramanuj PP, de Magalhaes FJC, Pincus HA, et al
    New and emerging treatments for major depressive disorder.
    BMJ. 2024;386:e073823.
    >> Share

    June 2024
  16. IACOBUCCI G
    Stopping antidepressants causes symptoms in one in six people, study estimates.
    BMJ. 2024;385:q1246.
    >> Share

    May 2024

  17. Effect of exercise for depression: systematic review and network meta-analysis of randomised controlled trials.
    BMJ. 2024;385:q1024.
    >> Share


  18. EXPRESSION OF CONCERN: Efficacy of psilocybin for treating symptoms of depression: systematic review and meta-analysis.
    BMJ. 2024;385:q1025.
    >> Share

  19. METAXA AM, Clarke M
    Efficacy of psilocybin for treating symptoms of depression: systematic review and meta-analysis.
    BMJ. 2024;385:e078084.
    >> Share

  20. DE GIORGI R, Ede R
    Psilocybin for depression.
    BMJ. 2024;385:q798.
    >> Share

    April 2024
  21. WANG S, Deng CM, Zeng Y, Chen XZ, et al
    Efficacy of a single low dose of esketamine after childbirth for mothers with symptoms of prenatal depression: randomised clinical trial.
    BMJ. 2024;385:e078218.
    >> Share

    March 2024
  22. FABIANO NT
    The effect of exercise on suicide in people with depression.
    BMJ. 2024;384:q609.
    >> Share

    February 2024
  23. BELLON JA
    Exercise for the treatment of depression.
    BMJ. 2024;384:q320.
    >> Share

  24. NOETEL M, Sanders T, Gallardo-Gomez D, Taylor P, et al
    Effect of exercise for depression: systematic review and network meta-analysis of randomised controlled trials.
    BMJ. 2024;384:e075847.
    >> Share

  25. RUSSELL AB, Slater J, Woods N
    Regulation of the illicit drugs industry will save lives and reduce misery.
    BMJ. 2024;384:q304.
    >> Share

  26. STUPAK R
    Reversing the rate of antidepressant prescribing: a view from Poland.
    BMJ. 2024;384:q234.
    >> Share

    January 2024
  27. HAGATULAH N, Brann E, Oberg AS, Valdimarsdottir UA, et al
    Perinatal depression and risk of mortality: nationwide, register based study in Sweden.
    BMJ. 2024;384:e075462.
    >> Share

  28. BRANN E, Shen Q, Lu D
    Perinatal depression and its health impact.
    BMJ. 2024;384:p2777.
    >> Share

    December 2023
  29. DAVIES J, Read J, Kruger D, Crisp N, et al
    Politicians, experts, and patient representatives call for the UK government to reverse the rate of antidepressant prescribing.
    BMJ. 2023;383:p2730.
    >> Share

    September 2023
  30. CHEN CC, Shao J, Liu Y, Gao Y, et al
    A man with ST segment depression.
    BMJ. 2023;382:e076079.
    >> Share

    August 2023
  31. MAHASE E
    US approves daily pill for postpartum depression.
    BMJ. 2023;382:p1822.
    >> Share

    July 2023
  32. THOMBS BD, Markham S, Rice DB, Ziegelstein RC, et al
    Screening for depression and anxiety in general practice.
    BMJ. 2023;382:1615.
    >> Share

  33. NOGRADY B
    Australia's approval of MDMA and psilocybin for PTSD and depression is premature, say critics.
    BMJ. 2023;382:p1599.
    >> Share

    June 2023
  34. WISE J
    Review that questioned serotonin theory of depression was flawed, say researchers.
    BMJ. 2023;381:1419.
    >> Share

    March 2023
  35. IACOBUCCI G
    NICE recommends online therapies to treat depression and anxiety in adults.
    BMJ. 2023;380:p495.
    >> Share


Free Medical Abstracts
Privacy Policy
Sponsors
Share

© Amedeo 1997-2016